The technology behind RESKIN is protected by an international patent application owned by ICN2 and CSIC and licensed exclusively worldwide to Tirecat Health.
Licensed to Tirecat HealthWO2022/258780
Bioinspired adhesive membrane for tissue regeneration
International patent application owned by ICN2 and CSIC (priority June 2021), with national phases in Europe, the United States, Canada, Australia, New Zealand, Israel, South Korea and Japan. Tirecat Health holds an exclusive worldwide licence, and a freedom-to-operate analysis found no blocking patents.
Want to know more about the technology?
Read how RESKIN works and where it stands, or write to us.
Technology and pipeline Contact us